

Ifw



DOCKET NO.: CELL-0286/P0143-USW01
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Stephen Martin Courtney, et al.

Confirmation No.: 1693

Application No.: 10/506,388

Group Art Unit: Not Yet Assigned

Filing Date: April 14, 2005

Examiner: Not Yet Assigned

For: PHTHALIMIDE CARBOXYLIC ACID DERIVATIVES

DATE OF DEPOSIT: September 13, 2005

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE UNITED STATES PATENT AND TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

Elizabeth A. McLoud

TYPED NAME: Elizabeth A. McLoud

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- ☒ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of

the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

- ☐ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with § 1.97(e) is attached; or

☐ The fee of **\$180.00** as set forth in § 1.17(p) is attached.

- ☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of **\$180.00** as set forth in § 1.17(p).

- ☒ Copies of reference numbers **1 - 18** listed on the attached Form PTO-1449 are enclosed herewith.

- ☐ Copies of reference numbers - on the attached Form PTO 1449 are not required to be submitted pursuant to 37 CFR § 1.98(a)(2)(i).

- ☐ Copies of references - are not being submitted because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application number , filed for which a claim for priority under 35 U.S.C. § 120 has been made in the instant application.

DOCKET NO.: CELL-0286/P0143-USW01
PATENT


- 3 -

☐ The relevance of those listed references which are not in the English language is as follows:

There are no listed references which are not in the English language.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Date: *September 13, 2005*



Jane E. Inglese
Registration No. 48,444

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

© 2005 WW



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. CELL-0286/ P0143-USw01	Application No. 10/506,388
		Applicant Stephen Martin Courtney, et al.	
		Filing Date April 14, 2005	Group Not Yet Assigned
		Confirmation No. 1693	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	1	Bashkin, P., et al., "Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules," <i>Biochem.</i> , 1989 , 28, 1737-1743	
	2	Database Chemcats Online, <i>CAS</i> , Database Accession No. 1575853, 2001 , XP002240053, order number A0827/0038765, 1 page	
	3	Database Chemcats Online, <i>CAS</i> , Database Accession No. 604372, 2001 , XP002240054, order number CHS 1040578, 1 page	
	4	Database Chemcats Online, <i>CAS</i> , Database Accession No. 126220, 2001 , XP002240055, order number 2922-0873, 1 page	
	5	Demir, M., et al., "Anticoagulant and antiprotease profiles of a novel natural heparinomimetic mannopentaoase phosphate sulfate (PI-88)," <i>Clin. Appl. Thromb Hemost</i> , 2001 , 7(2), 131-140	
	6	Fang, J., et al., "Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model," <i>Proc. Natl. Acad. Sci. USA</i> , 2000 , 97(8), 3884-3889	
	7	Folkman, J., et al., "Control of angiogenesis by heparin and other sulfated polysaccharides," <i>Adv. Exp. Med. Biol.</i> , 1992 , 313, 355-364	
	8	Kondragnati, S., et al., "Selective suppression of matrix metalloproteinase-9 in human glioblastoma cells by antisense gene transfer impairs glioblastoma cell invasion," <i>Cancer Res.</i> , 2000 , 60, 6851-6855	
	9	Parish, C.R., et al., "Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel <i>in vitro</i> assays for angiogenesis," <i>Cancer Res.</i> , 1999 , 59, 3433-3441	
	10	Parish, C.R., et al., "Treatment of central nervous system inflammation with inhibitors of basement membrane degradation," <i>Immunol. & Cell Biol.</i> , 1998 , 76, 104-113	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. CELL-0286/ P0143-USw01	Application No. 10/506,388
		Applicant Stephen Martin Courtney, et al.	
		Filing Date April 14, 2005	Group Not Yet Assigned
		Confirmation No. 1693	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	11	Takuji, H., et al., "Thermoplastic polyester resin composition," <i>Patent Abstracts of Japan</i> 1989, esp@cenet database, 1 page	
	12	Tyle, P., "Iontophoretic devices for drug delivery," <i>Pharmaceutical Res.</i> , 1986, 3(6), 318-326	
	13	Vlodavsky, I., et al., "Inhibition of tumor metastasis by heparanase inhibiting species of heparin," <i>Invasion Metastasis</i> , 1994-95, 14, 290-302	
	14	Vlodavsky, I., et al., "Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis," <i>Nature Medicine</i> , 1999, 5(7), 793-802	
EXAMINER		DATE CONSIDERED	

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. CELL-0286/ P0143-USw01	Application No. 10/506,388
	Applicant Stephen Martin Courtney, et al.	
	Filing Date April 14, 2005	Group Not Yet Assigned
	Confirmation No. 1693	

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
	15	WO 01/35967 A1	05/25/01	PCT		
	16	WO 02/060373 A3	08/08/02	PCT		
	17	01-247453	03/10/89	JP	X abstract	
	18	63-073425	04/04/88	JP	X abstract	

EXAMINER	DATE CONSIDERED
-----------------	------------------------